Critical Path Institute’s Critical Path for Rare Neurodegenerative Diseases consortium, will convene partners from the U.S. Food and Drug Administration, National Institutes of Health, Foundation for the National Institutes of Health, and the amyotrophic lateral sclerosis lived experience community to discuss progress under the public-private partnerships established under the Accelerating Access to Critical Therapies for ALS Act.
Additional details will be posted as they are confirmed.
